BR0115833A - Derivados condensados de purina como antagonistas de receptores de adenosina a1 - Google Patents

Derivados condensados de purina como antagonistas de receptores de adenosina a1

Info

Publication number
BR0115833A
BR0115833A BR0115833-3A BR0115833A BR0115833A BR 0115833 A BR0115833 A BR 0115833A BR 0115833 A BR0115833 A BR 0115833A BR 0115833 A BR0115833 A BR 0115833A
Authority
BR
Brazil
Prior art keywords
purine
adenosine
receptor antagonists
condensate derivatives
compounds
Prior art date
Application number
BR0115833-3A
Other languages
English (en)
Inventor
Ko-Chung Lin
Chi Vu
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR0115833A publication Critical patent/BR0115833A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS CONDENSADOS DE PURINA COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A~ 1~". A presente invenção refere-se a compostos de Fórmulas I e II como antagonistas de receptores de adenosina subtipo A~ 1~. Esses compostos são úteis para tratamento de várias doenças e distúrbios, incluindo hipertensão sistêmica, insuficiência renal, diabetes, asma, uma condição edematosa, insuficiência cardíaca congestiva e disfunção renal.
BR0115833-3A 2000-12-01 2001-11-30 Derivados condensados de purina como antagonistas de receptores de adenosina a1 BR0115833A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
BR0115833A true BR0115833A (pt) 2003-10-28

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115833-3A BR0115833A (pt) 2000-12-01 2001-11-30 Derivados condensados de purina como antagonistas de receptores de adenosina a1

Country Status (32)

Country Link
US (2) US6605601B2 (pt)
EP (1) EP1347981B1 (pt)
JP (2) JP2004514723A (pt)
KR (1) KR20040011439A (pt)
CN (1) CN100497340C (pt)
AR (1) AR035400A1 (pt)
AT (1) ATE394402T1 (pt)
AU (2) AU1997702A (pt)
BG (1) BG107849A (pt)
BR (1) BR0115833A (pt)
CA (1) CA2430508C (pt)
CZ (1) CZ20031513A3 (pt)
DE (1) DE60133931D1 (pt)
EA (1) EA009814B1 (pt)
EE (1) EE200300260A (pt)
ES (1) ES2305139T3 (pt)
GE (1) GEP20094697B (pt)
HU (1) HUP0400530A3 (pt)
IL (1) IL156046A0 (pt)
IS (1) IS6821A (pt)
MX (1) MXPA03004857A (pt)
MY (1) MY127120A (pt)
NO (1) NO20032483L (pt)
NZ (1) NZ526511A (pt)
PL (1) PL362642A1 (pt)
SK (1) SK6552003A3 (pt)
TR (1) TR200300766T2 (pt)
TW (1) TWI293301B (pt)
UA (1) UA75625C2 (pt)
WO (1) WO2002044182A1 (pt)
YU (1) YU42903A (pt)
ZA (2) ZA200304067B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
BR0115833A (pt) * 2000-12-01 2003-10-28 Biogen Inc Derivados condensados de purina como antagonistas de receptores de adenosina a1
JP2006518390A (ja) * 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
KR20060005376A (ko) * 2003-04-25 2006-01-17 교와 핫꼬 고교 가부시끼가이샤 축합 피리미딘 유도체
MXPA05011371A (es) 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
JP2008534445A (ja) * 2005-03-11 2008-08-28 アデリス ファーマシューティカルズ， インコーポレイテッド 置換９−アルキルアデニンおよびその使用
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
UA92083C2 (ru) 2006-05-19 2010-09-27 Эбботт Леборетриз Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
WO2007150025A2 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
KR20090025262A (ko) 2006-06-23 2009-03-10 인사이트 코포레이션 Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CA3087655A1 (en) 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
WO1993006079A1 (en) 1991-09-23 1993-04-01 Florida State University PREPARATION OF SUBSTITUTED ISOSERINE ESTERS USING METAL ALKOXIDES AND β-LACTAMS
AU4471297A (en) * 1996-10-07 1998-05-05 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
EP1014995A4 (en) * 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
EP1092435B1 (en) * 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
BR0115833A (pt) * 2000-12-01 2003-10-28 Biogen Inc Derivados condensados de purina como antagonistas de receptores de adenosina a1

Also Published As

Publication number Publication date
US20020111333A1 (en) 2002-08-15
UA75625C2 (en) 2006-05-15
CA2430508A1 (en) 2002-06-06
IL156046A0 (en) 2003-12-23
TWI293301B (en) 2008-02-11
MXPA03004857A (es) 2003-08-19
CZ20031513A3 (cs) 2003-09-17
PL362642A1 (en) 2004-11-02
ATE394402T1 (de) 2008-05-15
ZA200304067B (en) 2005-05-30
ZA200408755B (en) 2005-07-27
EA009814B1 (ru) 2008-04-28
TR200300766T2 (tr) 2004-09-21
YU42903A (sh) 2006-05-25
ES2305139T3 (es) 2008-11-01
US7022686B2 (en) 2006-04-04
HUP0400530A2 (hu) 2004-06-28
BG107849A (bg) 2004-01-30
CN100497340C (zh) 2009-06-10
EP1347981B1 (en) 2008-05-07
SK6552003A3 (en) 2003-12-02
NO20032483L (no) 2003-07-30
MY127120A (en) 2006-11-30
WO2002044182A1 (en) 2002-06-06
JP2004514723A (ja) 2004-05-20
NO20032483D0 (no) 2003-06-02
CN1481387A (zh) 2004-03-10
US6605601B2 (en) 2003-08-12
IS6821A (is) 2003-05-20
EE200300260A (et) 2003-08-15
HK1059927A1 (en) 2004-07-23
AR035400A1 (es) 2004-05-26
EP1347981A1 (en) 2003-10-01
AU1997702A (en) 2002-06-11
CA2430508C (en) 2010-05-18
DE60133931D1 (de) 2008-06-19
US20030220358A1 (en) 2003-11-27
EA200300629A1 (ru) 2003-12-25
NZ526511A (en) 2005-04-29
HUP0400530A3 (en) 2007-05-29
KR20040011439A (ko) 2004-02-05
AU2002219977B2 (en) 2008-01-24
JP2010053148A (ja) 2010-03-11
GEP20094697B (en) 2009-06-10

Similar Documents

Publication Publication Date Title
BR0115833A (pt) Derivados condensados de purina como antagonistas de receptores de adenosina a1
DK1444233T3 (da) A2B-adenosinreceptorantagonister
PT1054887E (pt) Derivados biciclicos de piridina e pirimidina como antagonistas de receptores no neuropeptido y
ES2195943T3 (es) Compuestos heteroaromaticos biciclicos y triciclicos.
EA200200921A1 (ru) Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
DE69034103D1 (de) Imidazoalkensäure
BRPI0510762A (pt) derivados de tetraidronaftiridina úteis como ligantes do receptor de histamina h3
EP1074549A3 (en) Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
ATE242254T1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
NO20022238L (no) Polycykloalkyl-puriner som adenosinreseptor-antagonister
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
ATE103604T1 (de) Substituierte 5-((tetrazolyl)alkenyl>-imidazole.
WO2002044142A3 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
JP2004511522A5 (pt)
ATE119524T1 (de) Substituierte n-(imidazolyl)alkyl-alanin- derivate.
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
CO5460266A1 (es) Novedosos analogos de la somatostatina
NO20002655D0 (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
BR0214582A (pt) Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements